| 日時 | 2021年9月11日（土）12:40～13:10 |
|---|---|
| 会場 | オンライン開催 オンデマンド配信：～12月31日（金）まで |
| 座長 | Dr. Hiroyuki Mano, National Cancer Center, Tokyo, Japan |
| 演題 | Genomes for Precision Oncology |
| 演者 | David Bentley, Vice President and Chief Scientist, Illumina Inc. |
| 要旨 | DNA sequencing is enabling routine adoption of genomic information in precision oncology. Comprehensive genomic profiling (CGP) is being adopted as an alternative to a multitude of small panels and single gene tests. This approach is providing a foundation to match more therapies to mutation data for better outcomes, to better support enrolment of patients on new clinical trials, and to define mutational signatures that inform new approaches to treatment. Studies are underway to derive evidence of clinical utility of CGP. With the benefit of technology improvements, whole genome and transcriptome sequencing is becoming accessible as a combined rapid test that will provide the most comprehensive profile of the tumor and germline genomes. A range of concept studies in acute leukemias, pediatric cancers and other solid tumors including breast cancer have shown evidence for improved actionable information, more precise treatment choices and better outcomes. Some healthcare systems (including the UK) are starting to adopt WGS for selected cancers. Further development of end-to-end workflows, a knowledge-based ecosystem, and clinical and economic evidence will support the widespread implementation of genomics in risk profiling, early detection, treatment and monitoring of all cancer types, as healthcare evolves to embrace precision oncology. |